BOSTON--(BUSINESS WIRE)--Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, provided a development update for its investigational drugs, Bendavia and Ocuvia, and announced future clinical plans for its orphan mitochondrial disease program at the 2015 United Mitochondrial Disease Foundation (UMDF) National Symposium in Washington, D.C. UMDF is a leading patient advocacy organization for those with inherited mitochondrial diseases, promoting patient-focused research and education, and supporting its members and their families. Inherited mitochondrial diseases encompass a diverse group of rare genetic disorders caused by mitochondrial dysfunction that severely impair patient well-being and quality of life.
Help employers find you! Check out all the jobs and post your resume.
